Erythroid Progenitor Cell Line for Hematological Disease Applications

Plasmodium vivax (malaria) is a significant health concern in many parts of Asia, Latin America, North Africa, and the Middle East. There is a lack of continuous culture systems for this pathogen. The subject technology is an erythroid progenitor continuous cell line (termed CD36E) identified by erythroid markers CD36, CD33, CD44, CD71, CD235, and globoside. These CD36E cells are heterozygous for Fya and Fyb (Duffy antigen). Due to recent evidence that Plasmodium vivax (P. vivax) can infect erythroid progenitor cells (reference: YX Ru et al. and T Panichakul et al.), these cells can be potentially used for culturing P. vivax and other species of malaria. This in turn could aid development of malaria related treatments and/or products. In addition, the cell line can also be used for other hematological disease applications that involve red blood cells or red blood cell precursors. The CD36E cells also produce alpha, beta, and chi hemoglobin and therefore may be used for research involving hemoglobin.

Potential Commercial Applications: Competitive Advantages:
  • Culture system for Plasmodium species (malaria)
  • Hematological diseases
 Immortalized erythroid progenitor cell line

Development Stage:
In vitro data can be provided upon request.


Susan Wong (NHLBI)  ➽ more inventions...

Ning Zhi (NHLBI)  ➽ more inventions...

Neal Young (NHLBI)  ➽ more inventions...

Intellectual Property:
Research Tool -- patent protection is not being pursued for this technology

YX Ru et al. Invasion of erythroblasts by Pasmodium vivax: A new mechanism contributing to malarial anemia. Ultrastruct Pathol. 2009 Oct;33(5):236-242. PubMed: 19895296
T Panichakul et al. Production of erythropoietic cells in vitro for continuous culture of Plasmodium vivax. Int J Parasitol. 2007 Dec;37(14):1551-1557. PubMed: 17610880

Collaboration Opportunity:

The National Heart Lung and Blood Institute, Hematology Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the CD36E cell line. Please contact Cecilia Pazman, Ph.D., at for more information.

Licensing Contact:
Vidita Choudhry, Ph.D.
Phone: 301-594-4095

OTT Reference No: E-151-2010-0
Updated: Feb 28, 2011